Our discovery that baseline differences exist in the olfactory neuronal expression of GSK3β comparing BD subjects to controls, strengthened by the inverse correlation between post-treatment mania symptom severity and treatment-associated downregulation of GSK3β levels, supports a future extension to study in vitro treatment-associated gene and protein levels in olfactory neuronal cultures of patients with known clinical response to lithium, to determine which of these predicts clinical response more accurately. The gene discussed is GSK3B; the disease is Behcet disease.